Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05276726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Feb 2026 → Aug 2027
See other at-risk trials from Allist Pharmaceuticals, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Feb 2026 to Aug 2027v8
  2. Lead sponsor: Jacobio Pharmaceuticals Co., Ltd. to Allist Pharmaceuticals, Inc.
    • Primary completion date: Dec 2023 to Feb 2026
    • Site contacts updated at 1 of 21 sites
    v7
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2022 to Aug 17, 2022
    • Site details revised at 21 of 21 sites
    v6
  4. Start date: Jul 2022 to Aug 2022v5
  5. Start date: Jun 2022 to Jul 2022v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Apr 2022 to Jun 2022v3
  2. Study title expanded, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Trial Details
NCT Number NCT05276726
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov